Brind.

Galapagos and Takeda entered a collaboration and licensing agreement for TYK2 inhibitor development.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Galapagos and Takeda entered a collaboration and licensing agreement for TYK2 inhibitor development.

Who's involved

What this event is mainly about
GalapagosTakeda

Keep exploring

The entities involved

  • Galapagos

    biotechnology company based in Leiden, Netherlands

    Nothing else this week.

  • Takeda

    company in Rome, Italy

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • PR NewswireTYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight The TYK2 inhibitor market is expected to witness substantial growth in the comi